Drug Profile

Bevifibatide - Bio-Thera Solutions

Alternative Names: BAT-2094; Batifiban - Bio-Thera Solutions; Betagrin; Correctin - Bio-Thera Solutions

Latest Information Update: 09 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bio-Thera Solutions
Class Antiplatelets; Cardiovascular therapies; Cyclic peptides
Mechanism of Action Integrin alphaVbeta3 antagonists; Platelet glycoprotein GPIIb-IIIa complex anatgonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Registered Acute coronary syndromes

Most Recent Events

02 Dec 2024 Zhujiang Hospital plans a phase II BCAIS-I trial for Acute ischemic stroke in China (IV) (NCT06712004)
07 Aug 2024 Chemical structure information updated
28 Jun 2024 Registered for Acute coronary syndromes in China (IV) - First global approval

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com